"We entered 2023 with renewed enthusiasm, energized by our clinical development progress and our goal to provide potentially best-in-class anti-FcRn therapies for people with autoimmune disorders," said Pete Salzmann, M.D., chief executive officer at Immunovant. "With an expected cadence of multiple data readouts beginning mid-2023, we believe we are poised for a transformative year for the class."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
- Immunovant participates in a conference call hosted by Truist
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- Immunovant upgraded to Overweight from Equal Weight at Wells Fargo
- Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald